Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data

Alnylam Pharmaceuticals, Inc. Discloses Deaths, Waits for More Data


Of course, it wasn't the actual earnings that caused the decline -- for the record, the biotech lost $104 million and ended the quarter with almost $1.2 billion in the bank -- but investors appear to be worried about the biotech's RNAi platform after Alnylam Pharmaceuticals reported further details about its phase 3 revusiran trial for patients with ATTR amyloidosisthat was stopped early because of an imbalance in the number of deaths between patients getting revusiran and those getting placebo. Alnylam had previously disclosed that there were 18 deaths in the clinical trial.



from Biotech News